The profits of Catalan pharmaceutical company Grífols in 2013 grew by 34.6% over the previous year, reaching €345.6 million, as reported by the multinational to the Spanish Stock Exchange Regulation Authority...
The Catalan pharmaceutical company posted a net profit of €182.2 million between January and June 2013, which represents an increase of 36.9% on the same period of 2012. 92.1% of Grífols sales are made abroad and this figure has...
The company, which is based in Greater Barcelona, is the world’s third leader in blood derivatives pharmaceutical products. Last year, it bought out its main competitor in the United States, Talecris. Grífols had a €2.62 billion turnover in...
The Catalan pharmaceutical company Grifols, the third world leader in the production of blood plasma based technologies, has seen its turnover increase by 15% in the first half of 2012 to €1.32 billion. Its net profit for the first half of...
The Catalan pharmaceutical company is the world’s leader in blood-derived products. After expanding in the United States by purchasing Talecris, Grifols needed a larger headquarters. It moved to three interconnected buildings in Sant Cugat del...
